Abstract: The present invention provides a compound represented by formula (I), a production method thereof, a production intermediate of the same and a method for producing compound B using the compound (I). Compound B is useful as an intermediate for producing compound A that is a BTK inhibitor.

Abstract: The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element.” In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element,” but include at least a portion of a bacterial origin of replication.

Abstract: The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element.” In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element,” but include at least a portion of a bacterial origin of replication.

Abstract: The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Abstract: A method and apparatus for measuring cells and cell confluence includes an imager for imaging a z-stack of bright field images and a processor for selecting a best focus bright field image at a z position of f microns in the z-stack of images. In the manner described herein, the processor selects a bright image n microns lower in the z-stack than the best focus bright field image and a dark image m microns higher in the stack than the best focus bright field image. The processor applies edge detection to the dark image to obtain an edge image and subtracts the edge image from the dark image and the processor applies an adaptive threshold to the bright image to create a mask and uses the adaptive thresholded image as seeds to evaluate the edge image to find cell candidates.

Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

Abstract: Provided herein is the identification of the causal gene KR associated with THCV, THCVA, CBDV, CBDVA, CBGV, CBGVA, CBCV, or CBCVA production in Cannabis plants. Also included are isolated cells, nucleic acids, transgenic Cannabis plants; methods of editing, and methods of using marker assisted selection to select and establish plant lines having modified THCV, THCVA, CBDV, CBDVA, CBGV, CBGVA, CBCV, or CBCVA activity.

Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

Abstract: Provided herein are VHH-containing polypeptides that bind NKp46. Uses of the VHH-containing polypeptides are also provided.

Abstract: Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.

Abstract: Thin-film mesh for medical devices and related methods are provided. The thin-film mesh may include slits to be expanded into pores, and the expanded thin-film mesh may be used as a cover for a stent device. The thin-film mesh has a tube-shape and the slits may be angled with respect to a longitudinal axis of the tube-shape thin-film mesh. The angled slits allow for the thin-film mesh to expand in multiple dimensions, including along the longitudinal axis and along the circumferential direction of the tube-shape thin-film mesh. The slits may be provided in diagonal rows arranged in longitudinal columns. Longitudinal columns of different types of slits may be arranged along the circumferential direction on the tube-shape thin-film mesh to form a zig-zag pattern of slits. The thin-film mesh may be formed from thin-film Nitinol (TFN) and may be fabricated via sputter deposition on a micropatterned wafer.

Abstract: This invention provides rho-associated protein kinase (ROCK) inhibiting compounds for therapeutic applications as described further herein.

Abstract: A compact sorting flow cytometer system includes a fluidics system having a flow cell and a deflection chamber in communication with the flow cell and a droplet deposition unit (DDU) system in communication with the deflection chamber. The defection chamber receives drops in a stream of a sample biological fluid with one or more biological cells or particles and selectively deflect the drops in the stream. The DDU system is in communication with the deflection chamber to receive the selectively deflected drops into one or more containers. The DDU system includes a case forming a portion of a containment chamber. When closed, one or more doors seal and close off the containment chamber from an external environment. Air can be evacuated from the containment chamber by one or more fans in one or more tunnels. Air can be conditioned by a thermoelectric cooling array between the containment chamber and an air conditioning chamber that is moved by one or more fans.

Abstract: The present invention discloses an anti-aging Chinese herb extract, an extraction method and a use thereof. The ginseng-Astragalus membranaceus extract of the present invention comprises 20 to 30% of astragaloside, 1 to 5% of ginsenoside Rg1, 2 to 6% of ginsenoside Re, 0.2 to 0.5% of ginsenoside Rb1. There are 17 characteristic peaks in high-performance liquid chromatography fingerprints of the extract. The extract can effectively improve activity of telomerase, delay cell aging, and can be applied to preparation of an anti-aging product.

Abstract: The application relates to the field of oncology, cancer immunotherapy, molecular biology and recombinant nucleic acid technology. In particular, the invention relates to genetically-modified eukaryotic cells comprising modulated TGF Beta signaling. The application further relates to the use of such genetically-modified eukaryotic cells for treating a disease, including cancer, in a subject.

Abstract: Compounds capable of selectively modulating the TLR signaling pathway provide an improved treatment method for a broad variety of diseases in both animals and humans. The mechanisms of action in the treatment and/or prevention of coccidiosis and other conditions related to gut inflammation are via a direct effect on innate and adaptive immune pathways. The downstream results are improvements in performance parameters related to gut health (including altering gut microbes, conversion rates, and body weight gains among others. When administered to animals, the bioactives of the disclosed inventive compound mitigate the effects of coccidiosis via an enhanced immune response rather than a direct effect on parasites, such as the Eimeria parasite. The mechanisms of action of the disclosed inventive compound and method are via immune system priming rather than a direct effect on pathogens, thus there is no risk of treatment resistance being developed.

Abstract: Provided herein is the identification of genetic markers associated with modified cannabinoids relating to levels or ratios of one or more of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromene (CBC), or cannabigerovarin (CBGV). The markers are useful for breeding plants having modified cannabinoids by obtaining nucleic acids, detecting one or more markers that indicate modified cannabinoids, and establishing plant lines having such characteristics.

Abstract: A user interface wizard generated by AI software walks a user through setting up an artificial intelligence (AI) image analysis experiments on multispectral cellular images using AI image analysis algorithms and AI feature analysis algorithms. In a training experiment mode, a new AI model a new AI model can be trained for a desired experiment on training image cellular data of biological cells in a sample and subsequently to run a classification experiment in a classification mode to classify new image cellular data of biological cells in the sample using the new AI model.

Abstract: Provided herein are compositions and methods for the multiplexed profiling of RNA and DNA modifications across transcriptomes and genomes, respectively. The methods combine molecular recognition of non-canonical features (e.g., base modifications, backbone modifications, lesions, and/or structural elements) of a target nucleic acid with a step of writing the information from this recognition event into the neighboring genetic sequence of the target nucleic acid using a barcode. The resultant barcoded nucleic acids are then converted into sequencing libraries and read by DNA/RNA sequencing methods. This step reveals the sequence of the barcode, which is correlated with the non-canonical feature in the target nucleic acid(s). The high throughput profiling methods described herein allow for identification and/or localization of one or more modifications in a target nucleic acid. The methods also allow for identification of the nature and location of several or all DNA/RNA modifications in parallel.